

Cancer Vaccines Market by Type (Preventive, Therapeutic (Neoantigen)), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Speciality Clinics) - Global Forecast to 2032

Market Report | 2024-12-19 | 263 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global cancer vaccines market is projected to surpass USD 20.47 billion in 2032 from USD 10.61 billion in 2024, with a significant CAGR of 8.6%. The market is witnessing robust growth, fueled by rising cancer prevalence and advancements in immunotherapy technologies like mRNA platforms. Preventive vaccines such as Gardasil (HPV) and therapeutic candidates like neoantigen vaccines are driving innovation in the market. Strong R&D investments, especially in North America and Europe, combined with increasing demand for personalized therapies, are further accelerating adoption.

"The preventive cancer vaccines segment accounted for the highest share in 2023."

On the basis of type, the cancer vaccines market is further segmented into preventive and therapeutic vaccines (Neoantigen cancer vaccines and other cancer vaccines). The preventive cancer vaccines segment is anticipated to lead the cancer vaccines market, driven by increasing awareness of disease prevention, government immunization programs, and technological advancements in vaccine development. Emerging technologies, such as mRNA platforms, are further likely to enhance vaccine efficacy and accessibility is likely to boost the segmental growth.

"By route of administration, intramuscular segment accounted for the largest share in the cancer vaccines market."

The route of administration segment of the cancer vaccines market is segmented into intravenous, intramuscular, and other route of administration. Intramuscular (IM) route of administration is expected to lead the cancer vaccines market owing to the established practice, high efficacy of the administration of the vaccine, and creation of an effective immune response. IM administration guarantees a high efficiency of vaccine absorption and compatibility with any kind of formulation, therefore it is the most appropriate for preventive and treatment cancer vaccines. Its ease of use in clinical and outpatient settings, along with

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

minimal training requirements for healthcare providers, enhances accessibility and scalability for mass immunization programs. All of these parameters therefore position the IM route as the dominant and feasible option in the cancer vaccine field.

"North America: the largest share of the cancer vaccines market"

By region, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America dominated the cancer vaccines market in 2023 and is estimated to continue dominance during the forecast period. Advanced healthcare infrastructure, high levels of investment in biotechnology, and strong presence of leading pharmaceutical companies driving innovation in the field, are some of the prominent factors accelerating market growth.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the cancer vaccines market.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 65% and Demand Side 35%

-□By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%

-□By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US) and Shanghai Zerun Biotechnology Co., Ltd. (China) among others are some of the major players operating in the cancer vaccines market.

Research Coverage:

This research report categorizes the cancer vaccines market type (preventive and therapeutic [neoantigen cancer vaccines & other cancer vaccines]), technology (cell-based vaccines, recombinant, others), route of administration (intramuscular, intravenous, other routes of administration), indication (cervical cancer, prostate cancer, other indications), end user (hospitals, others) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cancer vaccines market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the cancer vaccines market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the cancer vaccines and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

-□Analysis of key drivers (Increasing Awareness and Preventive Healthcare Measures, Rising Cancer Incidence Globally, Increased investments into R&D of Neoantigen cancer vaccines and Technological Advancements in Immunotherapy), restraints (Lengthy Clinical Trial Processes and Vaccine Hesitancy & Limited Adoption and High Development and Manufacturing Costs), opportunities (Collaborations & Strategic Partnerships and Incorporation of Artificial Intelligence (AI) & Big Data) and Challenges (Personalized Medicine & Heterogeneity of Cancer Types and Competition from Alternative Therapies) influencing the growth of the market.

-□Product Development/Innovation: Detailed insights on upcoming technologies in cancer vaccines manufacturing, research and development activities, and new product launches in the cancer vaccines market.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

-□Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cancer vaccines market

-□Competitive Assessment: Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US) and Shanghai Zerun Biotechnology Co., Ltd. (China) among others in the market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Table of Contents:

1	INTRODUCTION	26
1.1	STUDY OBJECTIVES	26
1.2	MARKET DEFINITION	26
1.3	MARKET SCOPE	27
1.3.1	MARKETS COVERED & REGIONAL SEGMENTATION	27
1.3.2	INCLUSIONS & EXCLUSIONS	28
1.3.3	YEARS CONSIDERED	28
1.3.4	CURRENCY CONSIDERED	28
1.4	STAKEHOLDERS	29
2	RESEARCH METHODOLOGY	30
2.1	RESEARCH DATA	30
2.1.1	SECONDARY DATA	31
2.1.2	PRIMARY DATA	32
2.2	MARKET ESTIMATION METHODOLOGY	33
2.2.1	MARKET ESTIMATION	33
2.2.2	INSIGHTS FROM PRIMARY EXPERTS	35
2.2.3	TOP-DOWN APPROACH	36
2.3	MARKET GROWTH RATE PROJECTION	37
2.4	DATA TRIANGULATION	39
2.5	RESEARCH ASSUMPTIONS	39
2.6	RESEARCH LIMITATIONS	40
2.7	RISK ANALYSIS	41
3	EXECUTIVE SUMMARY	42
4	PREMIUM INSIGHTS	47
4.1	CANCER VACCINES MARKET OVERVIEW	47
4.2	NORTH AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023)	48
4.3	CANCER VACCINES MARKET SHARE, BY TYPE, 2024 VS. 2032	48
4.4	CANCER VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	49
?		
5	MARKET OVERVIEW	50
5.1	INTRODUCTION	50
5.2	MARKET DYNAMICS	50
5.2.1	DRIVERS	51
5.2.1.1	Increased investments in neoantigen cancer vaccine R&D	51
5.2.1.2	Technological advancements in immunotherapy	51
5.2.1.3	Increasing awareness and preventive healthcare measures	52
5.2.1.4	Rising cancer incidence globally	53
5.2.2	RESTRAINTS	53
5.2.2.1	High development and manufacturing costs	53
5.2.2.2	Lengthy clinical trial processes & vaccine hesitancy and limited adoption	54
5.2.3	OPPORTUNITIES	55
5.2.3.1	Collaborations and strategic partnerships	55
5.2.3.2	Incorporation of AI and big data	56
5.2.4	CHALLENGES	57
5.2.4.1	Personalized medicine and heterogeneity of cancer types	57
5.2.4.2	Competition from alternative therapies	57

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS	58
5.4	VALUE CHAIN ANALYSIS	59
5.5	ECOSYSTEM ANALYSIS	60
5.5.1	RAW MATERIAL PROVIDERS	61
5.5.2	PRODUCT PROVIDERS	62
5.5.3	END USERS	63
5.5.4	REGULATORY LANDSCAPE	63
5.6	TECHNOLOGY ANALYSIS	64
5.6.1	KEY TECHNOLOGIES	65
5.6.1.1	mRNA-based vaccines	65
5.6.1.2	Dendritic cell vaccines	65
5.6.1.3	Recombinant vector-based vaccines	66
5.6.2	COMPLEMENTARY TECHNOLOGIES	66
5.6.2.1	Artificial Intelligence (AI) and Machine Learning (ML)	66
5.6.2.2	Adjuvants for immuno-stimulation	66
5.6.3	ADJACENT TECHNOLOGIES	67
5.6.3.1	CAR T-cell therapy	67
5.6.3.2	CRISPR-based gene editing	67
5.7	PATENT ANALYSIS	68
5.7.1	METHODOLOGY	68
5.7.2	NUMBER OF PATENTS FILED	68
5.7.3	INNOVATIONS AND PATENT APPLICATIONS	68
?		
5.8	PRICING ANALYSIS	71
5.8.1	AVERAGE SELLING PRICE TREND OF KEY PLAYERS, 2021-2023	71
5.8.2	AVERAGE SELLING PRICE, BY REGION, 2023	72
5.9	KEY CONFERENCES & EVENTS, 2024-2025	73
5.10	REGULATORY LANDSCAPE	74
5.10.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	74
5.10.2	REGULATORY FRAMEWORK	77
5.10.2.1	North America	77
5.10.2.2	Europe	77
5.10.2.3	Asia Pacific	77
5.11	INVESTMENT & FUNDING SCENARIO	78
5.12	PORTER'S FIVE FORCES ANALYSIS	80
5.12.1	INTENSITY OF COMPETITIVE RIVALRY	81
5.12.2	BARGAINING POWER OF SUPPLIERS	81
5.12.3	BARGAINING POWER OF BUYERS	81
5.12.4	THREAT OF SUBSTITUTES	81
5.12.5	THREAT OF NEW ENTRANTS	81
5.13	KEY STAKEHOLDERS & BUYING CRITERIA	82
5.13.1	KEY STAKEHOLDERS	82
5.13.2	KEY BUYING CRITERIA	83
5.14	TRADE ANALYSIS	85
5.14.1	IMPORT DATA FOR HS CODE 300241	85
5.14.2	EXPORT DATA FOR HS CODE 300241	86
5.15	IMPACT OF AI/GEN AI ON CANCER VACCINES MARKET	88

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.16	PIPELINE ANALYSIS	90
6	CANCER VACCINES MARKET, BY TYPE	91
6.1	INTRODUCTION	92
6.2	PREVENTIVE VACCINES	92
6.2.1	NATIONAL IMMUNIZATION PROGRAMS & BIOTECHNOLOGY INNOVATIONS TO DRIVE MARKET GROWTH	92
6.3	THERAPEUTIC VACCINES	95
6.3.1	NEOANTIGEN CANCER VACCINES	99
6.3.1.1	Personalized nature of neoantigen cancer vaccines to propel market growth	99
6.3.2	OTHER THERAPEUTIC VACCINES	102
7	CANCER VACCINES MARKET, BY TECHNOLOGY	106
7.1	INTRODUCTION	107
7.2	CELL-BASED VACCINES	107
7.2.1	ADVANCEMENTS IN MANUFACTURING PROCESSES TO DRIVE MARKET GROWTH	107
7.3	RECOMBINANT VACCINES	110
7.3.1	GLOBAL VACCINATION INITIATIVES TO PROPEL MARKET	110
7.4	OTHER VACCINE TECHNOLOGIES	113
8	CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION	117
8.1	INTRODUCTION	118
8.2	INTRAMUSCULAR ROUTE	118
8.2.1	TECHNOLOGICAL ADVANCEMENTS IN VACCINE DELIVERY TO SUPPORT MARKET GROWTH	118
8.3	OTHER ROUTES OF ADMINISTRATION	121
9	CANCER VACCINES MARKET, BY INDICATION	125
9.1	INTRODUCTION	126
9.2	CERVICAL & RELATED CANCERS	126
9.2.1	RIISING CERVICAL CANCER PREVALENCE TO SUPPORT MARKET GROWTH	126
9.3	OTHER INDICATIONS	129
10	CANCER VACCINES MARKET, BY END USER	133
10.1	INTRODUCTION	134
10.2	HOSPITALS	134
10.2.1	RIISING CANCER PREVALENCE TO SUPPORT MARKET GROWTH	134
10.3	SPECIALTY CLINICS & CENTERS	137
10.3.1	INCREASING AWARENESS AND ACCESS TO PROPEL MARKET	137
11	CANCER VACCINES MARKET, BY REGION	141
11.1	INTRODUCTION	142
11.2	ASIA PACIFIC	142
11.2.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	143
11.2.2	CHINA	147
11.2.2.1	Government support & strategic initiatives by key players to strengthen biotechnology sector in China	147
11.2.3	JAPAN	150
11.2.3.1	Government initiatives for vaccines to boost market	150
11.2.4	INDIA	152
11.2.4.1	Growth of biotechnology sector and development of new vaccines to drive market	152
11.2.5	SOUTH KOREA	155
11.2.5.1	Commitment to cancer immunotherapy to expand cancer vaccine sector	155
11.2.6	REST OF ASIA PACIFIC	157

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.3	NORTH AMERICA	160
11.3.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	160
11.3.2	US	164
11.3.2.1	US to dominate North American market during forecast period	164
11.3.3	CANADA	167
11.3.3.1	Increasing government funding for vaccine research to drive market growth in Canada	167
11.4	EUROPE	169
11.4.1	MACROECONOMIC OUTLOOK FOR EUROPE	169
11.4.2	GERMANY	173
11.4.2.1	Increasing investments by key players and growing funding from government organizations to drive market	173
11.4.3	UK	175
11.4.3.1	Rising investments in vaccine development to boost market growth	175
11.4.4	FRANCE	178
11.4.4.1	Support for biotechnology and research to drive market growth	178
11.4.5	ITALY	181
11.4.5.1	Government initiatives for vaccine development to boost market growth	181
11.4.6	SPAIN	183
11.4.6.1	Increasing investments in vaccine development by government and private organizations to support market growth	183
11.4.7	REST OF EUROPE	186
11.5	LATIN AMERICA	188
11.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	188
11.5.2	BRAZIL	191
11.5.2.1	Proactive healthcare policies to support market growth	191
11.5.3	MEXICO	194
11.5.3.1	Government commitment to immunization programs to fuel growth	194
11.5.4	REST OF LATIN AMERICA	196
11.6	MIDDLE EAST	198
11.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST	198
11.6.2	GCC COUNTRIES	202
11.6.3	REST OF MIDDLE EAST	204
11.7	AFRICA	206
11.7.1	INCREASING INVESTMENTS IN CANCER VACCINE IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH	206
11.7.2	MACROECONOMIC OUTLOOK FOR AFRICA	207
?		
12	COMPETITIVE LANDSCAPE	210
12.1	OVERVIEW	210
12.2	KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023	210
12.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER VACCINES MARKET	210
12.3	REVENUE ANALYSIS, 2019-2023	212
12.4	MARKET RANKING, 2023 AND 2032	212
12.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	214
12.5.1	STARS	214
12.5.2	EMERGING LEADERS	214
12.5.3	PERVASIVE PLAYERS	215
12.5.4	PARTICIPANTS	215
12.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	216
12.5.5.1	Company footprint	216

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.5.5.2	Region footprint	216
12.5.5.3	Type footprint	217
12.5.5.4	Technology footprint	217
12.5.5.5	Route of administration footprint	218
12.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	218
12.6.1	PROGRESSIVE COMPANIES	218
12.6.2	RESPONSIVE COMPANIES	218
12.6.3	DYNAMIC COMPANIES	218
12.6.4	STARTING BLOCKS	219
12.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	220
12.7	COMPANY VALUATION & FINANCIAL METRICS	221
12.7.1	FINANCIAL METRICS	221
12.7.2	COMPANY VALUATION	221
12.8	BRAND/PRODUCT COMPARISON	222
12.9	COMPETITIVE SCENARIO	222
12.9.1	PRODUCT LAUNCHES & APPROVALS	222
12.9.2	DEALS	223
12.9.3	EXPANSIONS	224
13	COMPANY PROFILES	225
13.1	KEY PLAYERS	225
13.1.1	MERCK & CO., INC.	225
13.1.1.1	Business overview	225
13.1.1.2	Products offered	226
13.1.1.3	Recent developments	227
13.1.1.3.1	Deals	227
13.1.1.3.2	Expansions	227
13.1.1.4	MnM view	228
13.1.1.4.1	Key strengths	228
13.1.1.4.2	Strategic choices	228
13.1.1.4.3	Weaknesses & competitive threats	228
13.1.2	GSK PLC.	229
13.1.2.1	Business overview	229
13.1.2.2	Products offered	230
13.1.2.3	Recent developments	231
13.1.2.3.1	Product approvals	231
13.1.2.4	MnM view	231
13.1.2.4.1	Key strengths	231
13.1.2.4.2	Strategic choices	231
13.1.2.4.3	Weaknesses & competitive threats	231
13.1.3	DENDREON PHARMACEUTICALS LLC. (SANPOWER GROUP)	232
13.1.3.1	Business overview	232
13.1.3.2	Products offered	232
13.1.3.3	MnM view	233
13.1.3.3.1	Key strengths	233
13.1.3.3.2	Strategic choices	233
13.1.3.3.3	Weaknesses & competitive threats	233

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.1.4	JW CREAGENE (JW SHINYAK)	234
13.1.4.1	Business overview	234
13.1.4.2	Products offered	234
13.1.5	SERUM INSTITUTE OF INDIA PVT. LTD.	235
13.1.5.1	Business overview	235
13.1.5.2	Products offered	235
13.1.5.3	Recent developments	236
13.1.5.3.1	Product launches	236
13.1.5.3.2	Deals	236
13.1.6	VERITY PHARMACEUTICALS, INC.	237
13.1.6.1	Business overview	237
13.1.6.2	Products offered	237
13.1.6.3	Recent developments	238
13.1.6.3.1	Product approvals	238
13.1.7	WANTAI BIOPHARM	239
13.1.7.1	Business overview	239
13.1.7.2	Products offered	239
13.1.8	SHANGHAI ZERUN BIOTECH CO., LTD. (WALVAX BIOTECHNOLOGY CO., LTD.)	240
13.1.8.1	Business overview	240
13.1.8.2	Products offered	240
13.1.8.3	Recent developments	241
13.1.8.3.1	Product approvals	241
13.1.9	VACCINOGEN	242
13.1.9.1	Business overview	242
13.1.9.2	Products offered	242
13.2	OTHER PLAYERS (COMPANIES WITH PRODUCTS UNDER CLINICAL STUDIES)	243
13.2.1	BIONTECH	243
13.2.1.1	BioNTech: Products under clinical studies	243
13.2.2	GRITSTONE BIO	244
13.2.2.1	Gritstone Bio: Products under clinical studies	244
13.2.3	OSE-IMMUNO	245
13.2.3.1	OSE-Immuno: Products under clinical studies	245
13.2.4	OBI PHARMA	246
13.2.4.1	OBI Pharma: Products under clinical studies	246
13.2.5	SHANGHAI BOVAX BIOTECHNOLOGY CO., LTD.	247
13.2.5.1	Shanghai Bovax Biotechnology: Products under clinical studies	247
13.2.6	MODERNA INC.	248
13.2.6.1	Moderna: Products under clinical studies	248
13.2.7	BEIJING SINOCELL BIOTECHNOLOGY GROUP CO., LTD.	249
13.2.7.1	Beijing Sinocell Biotechnology Group: Products under clinical studies	249
13.2.8	GREENWICH LIFESCIENCES, INC.	250
13.2.8.1	Greenwich LifeSciences: Products under clinical studies	250
13.2.9	ASTON SCI. INC.	251
13.2.9.1	Aston Sci.: Products under clinical studies	251
13.2.10	TRANSGENE	252
13.2.10.1	Transgene: Products under clinical studies	252
13.2.11	SELLAS LIFE SCIENCES GROUP INC.	253

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.2.11.1	Sellas Life Sciences Group: Products under clinical studies	253
14	APPENDIX	254
14.1	DISCUSSION GUIDE	254
14.2	KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL	259
14.3	CUSTOMIZATION OPTIONS	261
14.4	RELATED REPORTS	261
14.5	AUTHOR DETAILS	262

Cancer Vaccines Market by Type (Preventive, Therapeutic (Neoantigen)), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Speciality Clinics) - Global Forecast to 2032

Market Report | 2024-12-19 | 263 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-04
		Signature	<div></div>